222 related articles for article (PubMed ID: 12050532)
1. Re: Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?
Ansari MS
J Urol; 2002 Jul; 168(1):200; author reply 200-1. PubMed ID: 12050532
[No Abstract] [Full Text] [Related]
2. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
Rosser CJ; Parker A
J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093
[No Abstract] [Full Text] [Related]
3. [Diagnostic value of tissue and serum prostate specific antigen in prostate cancer].
Medvedev VL
Voen Med Zh; 2004 Feb; 325(2):50-4. PubMed ID: 15101295
[No Abstract] [Full Text] [Related]
4. [Diagnosis of prostate cancer].
Strittmatter F
MMW Fortschr Med; 2010 May; 152(19):40-2. PubMed ID: 20557001
[No Abstract] [Full Text] [Related]
5. Re: Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
Singh A
Can J Urol; 2009 Jun; 16(3):4659. PubMed ID: 19497173
[No Abstract] [Full Text] [Related]
6. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
7. PSA screening: the bottom line.
Elhilali MM
CMAJ; 2000 Mar; 162(6):791-2. PubMed ID: 10750466
[No Abstract] [Full Text] [Related]
8. Repeat prostate biopsy--when, where, and how.
Presti JC
Urol Oncol; 2009; 27(3):312-4. PubMed ID: 19414120
[TBL] [Abstract][Full Text] [Related]
9. [Detection of prostate cancer: yes or no?].
Van Cangh PJ
Bull Mem Acad R Med Belg; 2006; 161(3-4):159-69. PubMed ID: 17172224
[No Abstract] [Full Text] [Related]
10. Role of free prostate-specific antigen measurement in prostate-specific antigen screening for prostate cancer.
Johnson L
Clin Prostate Cancer; 2002 Dec; 1(3):142-4. PubMed ID: 15046688
[No Abstract] [Full Text] [Related]
11. [Clinical problems of systematic prostate needle biopsy in the detection of prostate cancer].
Suzuki H
Gan To Kagaku Ryoho; 2003 Jan; 30(1):16-20. PubMed ID: 12557699
[TBL] [Abstract][Full Text] [Related]
12. Re: The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy I. M. Thompson, C. M. Tangen, D. P. Ankerst, C. Chi, M. S. Lucia, P. Goodman, H. Parnes and C. A. Coltman, Jr. J Urol 2008; 180: 544-547.
Atmaca AF; Balbay MD
J Urol; 2009 May; 181(5):2387-8. PubMed ID: 19303084
[No Abstract] [Full Text] [Related]
13. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
Partin AW; Brawer MK; Bartsch G; Horninger W; Taneja SS; Lepor H; Babaian R; Childs SJ; Stamey T; Fritsche HA; Sokoll L; Chan DW; Thiel RP; Cheli CD
J Urol; 2003 Nov; 170(5):1787-91. PubMed ID: 14532777
[TBL] [Abstract][Full Text] [Related]
14. [The influence of prostate volume on the diagnostic parameters related to PSA and clinicopathological features of prostate cancer].
Kimura G; Kimata R; Saito Y; Yoshida K; Nishimura T
Nihon Rinsho; 2002 Dec; 60 Suppl 11():479-85. PubMed ID: 12599623
[No Abstract] [Full Text] [Related]
15. Assessing risk: does this patient have prostate cancer?
Carter HB
J Natl Cancer Inst; 2006 Apr; 98(8):506-7. PubMed ID: 16622114
[No Abstract] [Full Text] [Related]
16. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels.
Lawrentschuk N; Fleshner N
BJU Int; 2009 Mar; 103(6):730-3. PubMed ID: 19154475
[TBL] [Abstract][Full Text] [Related]
17. Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen, and Gleason score to predict prostate cancer recurrence after radical prostatectomy.
Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
Eur Urol; 2004 Nov; 46(5):571-8. PubMed ID: 15474265
[TBL] [Abstract][Full Text] [Related]
18. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
Gofrit ON; Zorn KC; Taxy JB; Lin S; Zagaja GP; Steinberg GD; Shalhav AL
J Urol; 2007 Nov; 178(5):1925-8. PubMed ID: 17868725
[TBL] [Abstract][Full Text] [Related]
19. [Prostate-specific antigen and its related parameters in detecting prostate cancer].
Kuruma H; Egawa S
Gan To Kagaku Ryoho; 2003 Jan; 30(1):11-5. PubMed ID: 12557698
[TBL] [Abstract][Full Text] [Related]
20. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for T1c prostate cancer.
Tanaka N; Fujimoto K; Yoshikawa M; Tanaka M; Hirao Y; Kondo H; Saito I
Hinyokika Kiyo; 2007 Jul; 53(7):459-65. PubMed ID: 17702178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
